medigraphic.com
ISSN 1527-3172 (Electronic)

2011, Number 2

<< Back Next >>

MEDICC Review 2011; 13 (2)

Drug-resistant HIV-1 in cuban children and their seropositive mothers

Pérez L, Correa C, Alemán CY, González I, Pérez J, Martínez PA, Álvarez A, Soto Y, Kourí V

Language: English
References: 49
Page: 24-31
PDF size: 268.37 Kb.


ABSTRACT

Introduction: The use of highly active antiretroviral therapy has reduced progression to AIDS and increased survival among seropositive persons; yet, appearance of resistant viruses may jeopardize these benefits. In Cuba, HIV mainly affects adults; at the end of 2009 of the 41 children infected, 25 were still alive; of these, 22 were under antiretroviral treatment. Until now, nothing was known about HIV-1 antiviral resistance and viral subtypes in the pediatric population in Cuba.
Objective: This study aims to identify presence of antiretroviralresistant HIV-1 strains in Cuban children and their mothers, and to provide a phylogenetic characterization and comparison of pol gene sequences in the same.
Methods: Plasma samples were collected from 22 children and their mothers, all HIV-1–infected, from 2004 through 2009. Reverse transcription polymerase chain reaction was used to amplify the pol gene fragment coding for HIV protease and reverse transcriptase enzymes; this was then sequenced and subjected to phylogenetic analysis of HIV subtypes and recombinant forms to compare sequences between mothers and children. HIV mutations conferring antiretroviral resistance were determined.
Results: Viral amplification was achieved in samples from 11 children and 8 mothers. Subtypes detected were: CRF19_cpx in five children, subtype B in three, CRF18_cpx in two, and subtype C in one child. In all mother–child pairs, samples were grouped within the same viral subtype in the phylogenetic tree. One mother was under treatment and five children had been treated before the sample was collected. In viruses amplified from samples of children under treatment, resistance was most frequently found to lamivudine (3 cases) and nevirapine (4 cases). Two untreated children carried resistant viruses possibly acquired from their mothers.
Conclusions This is the first study to describe HIV-1 antiviral resistance in the pediatric population in Cuba; it also identified viral subtypes infecting the mother−child pairs studied. We recommend antiretroviral resistance assays before initiating treatment in pregnant seropositive women and their newborns.


REFERENCES

  1. Clotet B, Menéndez-Arias L, Schapiro JM, Kuritzkes D, Burger D, Tural C, et al. Guide to management of HIV drug resistance, antiretrovirals pharmacokinetics and viral hepatitis infected subjects. Barcelona: Fundació de Lluita contra la SIDA; 2008. 430 p.

  2. Becquet R, Ekouevi DK, Arrive E, Stringer JS, Meda N, Chaix ML, et al. Universal Antiretroviral Therapy for Pregnant and Breast-Feeding HIV-1–Infected Women: Towards the Elimination of Mother-to-Child Transmission of HIV-1 in Resource-Limited Settings. Clin Infect Dis. 2009 Dec 15;49(12):1936–45.

  3. UNAIDS. AIDS epidemic update 2009 [Internet]. 2009 Nov [cited 2011 Mar 21]. Available from: http://data.unaids.org/pub/Report/2009/jc1700_ epi_update_2009_en.pdf

  4. Siegrist CA, Yerly S, Kaiser L, Wyler CA, Perrin L. Mother to child transmission of zidovudine-resistant HIV-1. Lancet. 1994 Dec 24–31;344(8939– 40):1771–2.

  5. Masquelier B, Chaix ML, Burgard M, Lechenadec J, Doussin A, Simon F, et al. Zidovudine Genotypic Resistance in HIV-1-Infected Newborns in the French Perinatal Cohort. J Acquir Immune Defi c Syndr. 2001 Jun 1;27(2):99–104.

  6. Johnson VA, Petropoulos CJ, Woods CR, Hazelwood JD, Parkin NT, Hamilton CD, et al. Vertical Transmission of Multidrug-Resistant Human Immunodefi ciency Virus Type 1 (HIV-1) and Continued Evolution of Drug Resistance in an HIV-1-Infected Infant. J Infect Dis. 2001 Jun 1;183(11):1688–93.

  7. Luzuriaga K, McManus M, Mofenson L, Britto P, Graham B, Sullivan JL, et al. A Trial of Three Antiretroviral Regimens in HIV-1–Infected Children. N Engl J Med. 2004 Jun 10;350(24):2471–80.

  8. Nolan M, Fowler MG, Mofenson LM. Antiretroviral Prophylaxis of Perinatal HIV-1 Transmission and the Potential Impact of Antiretroviral Resistance. J Acquir Immune Defi c Syndr. 2002 Jun 1;30(2):216–29.

  9. Palumbo P, Holland B, Dobbs T, Pau CP, Luo CC, Abrams EJ, et al. Antiretroviral Resistance Mutations Among Pregnant Human Immunodefi ciency Virus Type 1-Infected Women and Their Newborns in the United States: Vertical Transmission and Clades. J Infect Dis. 2001 Nov 1;184(9):1120–6.

  10. Delaugerre C, Chaix ML, Blanche S, Warszawski J, Cornet D, Dollfus C, et al. Perinatal acquisition of drugresistant HIV-1 infection: mechanisms and long-term outcome. Retrovirology. 2009 Sep 19;6:85.

  11. De Luca A, Prosperi M, Bracciale L. Resistance considerations in sequencing of antiretroviral therapy in low-middle income countries with currently available options. Curr Opin HIV AIDS. 2010 Jan;5(1):27–37.

  12. Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-infected women and prevention of perinatal HIV- 1 transmission. J Acquir Immune Defi c Syndr. 2002; 29:484–94.

  13. Warszawski J, Tubiana R, Le Chenadec J, Blanche S, Teglas JP, Dolfus C, et al. Motherto-child HIV transmission despite antirretroviral therapy in the ANRS French perinatal cohort. AIDS. 2008; 22:289–99.

  14. Pérez J, Pérez D, González I, Díaz Jidy M, Orta M, Aragonés C, et al. Approaches to the management of HIV/AIDS in Cuba [Internet]. Geneva: World Health Organization; 2004 [cited 2011 Mar 19]. 19 p. Available from: http://www.who.int/hiv/ pub/prev_care/en/cuba.pdf.

  15. Cancio I, Rocha N, Reymond V, Bermúdez R. Pautas para la atención integral al paciente con infección por VIH/sida en Cuba. Havana: Ministry of Public Health (CU); 2009. 62 p. Spanish.

  16. Kimura M. A simple method for estimating evolutionary rate of base substitution through comparative studies of nucleotide sequences. J Mol Evol. 1980 Dec;16(2):111–20.

  17. Kumar S, Tamura K, Nei M. MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform. 2004 Jun;5(2):150–63.

  18. Salminen MO, Carr JK, Burke DS, McCutchan FE. Identifi cation of breakpoints in intergenotypic recombinants of HIV type 1 by bootscanning. AIDS Res Hum Retroviruses. 1995 Nov;11(11):1423–5.

  19. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, et al. Full-Length Human Immunodefi ciency Virus Type 1 Genomes from Subtype C-Infected Seroconverters in India, with Evidence of Intersubtype Recombination. J Virol. 1999 Jan;73(1):152–60.

  20. Hillis DM, Allard MW, Miyamoto MM. Analysis of DNA sequence data: phylogenetic inference. Methods Enzymol. 1993;224:456–87.

  21. HIV Drug Resistance Database [Internet]. Stanford: Stanford University. c1998-2011 [cited 2011 Mar 10]. Available from: http://hivdb.stanford. edu/.

  22. Geelen SP. [HIV infection in children and the prevention of mother-to-child transmission]. Ned Tijdschr Geneeskd. 2002 Jul 6;146(27):1261–4. Dutch.

  23. Ferreira FG, Pinto JA, Kakehasi FM, Cleto S, Tupinambás U, Aleixo AW, et al. Prevalence of Primary Drug Resistance-Associated Mutations Among HIV Type 1 Vertically Infected Children in Belo Horizonte, Brazil. AIDS Res Hum Retroviruses. 2010 Feb 15;26(2):229–32.

  24. Villahermosa ML, Thomson M, Vázquez de Parga E, Cuevas MT, Contreras G, Pérez-Alvarez L, et al. Improved Conditions for Extraction and Amplifi cation of Human Immunodefi ciency Virus Type 1 RNA From Plasma Samples With Low Viral Load. J Hum Virol. 2000 Jan–Feb;3(1):27–34.

  25. Fontaine E, Riva C, Peeters M, Schmit JC, Delaporte E, Van Laethem K, et al. Evaluation of two commercial kits for the detection of genotypic drug resistance on a panel of HIV type 1 subtypes A through J. J Acquir Immune Defi c Syndr. 2001 Nov 1;28(3):254–8.

  26. Muñoz Fernández MA. [Virological diagnosis of HIV infection in children]. Allergol Immunopathol (Madr). 1998 May–Jun;26(3):122–9. Spanish.

  27. Sire JM, Vray M, Merzouk M, Plantier JC, Pavie J, Maylin S, et al. Comparative RNA Quantifi cation of HIV-1 Group M and Non-M With the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott Real Time HIV-1 PCR assays. J Acquir Immune Defi c Syndr. 2011 Mar 1;56(3):239–43.

  28. Blanco M, Rolo F, Martínez N, Gessa A, Díaz H, Lubián AL. Aplicación del ensayo de movilidad del heterodúplex en los estudios de epidemiología molecular del VIH-1 en Cuba. Biotecnología Aplicada. 2001;18(3):149–53. Spanish.

  29. Cuevas MT, Ruibal I, Villahermosa ML, Díaz H, Delgado E, Parga EV, et al. High HIV-1 genetic diversity in Cuba. AIDS. 2002 Aug 16;16(12):1643–53.

  30. Pérez L, Thomson MM, Bleda MJ, Aragonés C, González Z, Pérez J, et al. HIV Type 1 Molecular Epidemiology in Cuba: High Genetic Diversity, Frequent Mosaicism, and Recent Expansion of BG Intersubtype Recombinant Forms. AIDS Res Hum Retroviruses. 2006 Aug;22(8):724–33.

  31. Hasegawa N, Sugiura W, Shibata J, Matsuda M, Ren F, Tanaka H. Inferring within-patient HIV-1 evolutionary dynamics under anti-HIV therapy using serial virus samples with vSPA. BMC Bioinformatics. 2009 Oct 29;10:360.

  32. Buendia P, Narasimhan G. Sliding MinPD: building evolutionary networks of serial samples via an automated recombination detection approach. Bioinformatics. 2007 Nov 15;23(22):2993–3000.

  33. González Núñez I, Díaz Jidy M, Pérez Avila J. [Mother to child transmission of infantile HIV/ AIDS in Cuba]. Rev Cubana Med Trop. 2000 Sep–Dec;52(3):220–4. Spanish.

  34. González Núñez I, Díaz Jidy M, Pérez Ávila J, Mengana Gutiérrez HL. [Antiretroviral therapy in HIV/AIDS seropositive pregnant women in Cuba]. Rev Cubana Med Trop. 2004 JanApr;56(1):70–2. Spanish.

  35. Glikman D, Walsh L, Valkenburg J, Mangat PD, Marcinak JF. Hospital-based directly observed therapy for HIV-infected children and adolescents to assess adherence to antiretroviral medications. Pediatrics. 2007 May;119(5):e1142–8.

  36. Mullen J, Leech S, O’Shea S, Chrystie IL, Du Mont G, Ball C, et al. Antiretroviral drug resistance among HIV-1 infected children failing treatment. J Med Virol. 2002 Nov;68(3):299–304.

  37. Tsertsvadze T, Bolokadze N, Sharvadze L, Gabunia P, Dvali N. Antiretroviral treatment in Georgia. Georgian Med News. 2008 Dec;(165):10–6.

  38. Tornatore M, Gonçalves CV, Mendoza-Sassi RA, Silveira JM, D’Ávila NE, Maas CG, et al. HIV-1 vertical transmission in Rio Grande, Southern Brazil. Int J STD AIDS. 2010 May;21(5):351–5.

  39. Shafer RW. The challenge of antiretroviral drug resistance in HIV-1-infected children. J Pediatr (Rio J). 2009 Mar–Apr;85(2):91–4. English, Portuguese.

  40. Gupta RK, Gibb DM, Pillay D. Management of paediatric HIV-1 resistance. Curr Opin Infect Dis. 2009 Jun;22(3):256–63.

  41. Adjé-Touré C, Hanson DL, Talla-Nzussouo N, Borget MY, Kouadio LY, Tossou O, et al. Virologic and immunologic response to antiretroviral therapy and predictors of HIV type 1 drug resistance in children receiving treatment in Abidjan, Cote d’Ivoire. AIDS Res Hum Retroviruses. 2008 Jul;24(7):911–7.

  42. Zhang F, Haberer J, Wei H, Wang N, Chu A, Zhao Y, et al. Drug resistance in the Chinese National Pediatric Highly Active Antiretroviral Therapy Cohort: implications for paediatric treatment in the developing world. Int J STD AIDS. 2009 Jun;20(6):406–9.

  43. Vignoles M, Barboni G, Agosti MR, Quarleri J, Garcia MK, Ayala SG, et al. Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina. Antivir Ther. 2009;14(8):1175–81.

  44. Liu ZY, Wei HS, Zhao HX, Liu YN, Zhao Y, Han N, et al. [HIV-1 genotypic resistance profi les in children failing highly active antiretroviral therapy]. Zhonghua Yi Xue Za Zhi. 2007 Dec 11;87(46):3292–4. Chinese.

  45. Kamya MR, Mayanja-Kizza H, Kambugu A, Bakeera-Kitaka S, Semitala F, Mwebaze-Songa P, et al. Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defi c Syndr. 2007 Oct 1;46(2):187–93.

  46. Machado DM, Fernandes SC, Succi RC, Freire WS, Pannuti CS, Gouveia AB, et al. Analysis of HIV-type 1 protease and reverse transcriptase in Brazilian children failing highly active antiretroviral therapy (HAART). Rev Inst Med Trop Sao Paulo. 2005 Jan–Feb;47(1):1–5.

  47. Sungkanuparph S, Apiwattanakul N, Thitithanyanont A, Chantratita W, Sirinavin S. HIV-1 drug resistance mutations in children who failed non nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Southeast Asian J Trop Med Public Health. 2009 Jan;40(1):83–8.

  48. Simonetti SR, Schatzmayr HG, Simonetti JP. Human immunodefi ciency virus type 1: drug resistance in treated and untreated Brazilian children. Mem Inst Oswaldo Cruz. 2003 Sep;98(6):831–7.

  49. Mihailidis C, Dunn D, Pillay D, Pozniak A. Effect of isolated V118I mutation in reverse transcriptase on response to fi rst-line antiretroviral therapy. AIDS. 2008 Jan 30;22(3):427–30.




2020     |     www.medigraphic.com